Trust Co. of Vermont Takes Position in Abbott Laboratories $ABT

Trust Co. of Vermont purchased a new position in shares of Abbott Laboratories (NYSE:ABT) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 191,092 shares of the healthcare product maker’s stock, valued at approximately $17,340,000.

Other large investors have also modified their holdings of the company. Cornerstone Financial Management LLC purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at approximately $25,000. MidAtlantic Capital Management Inc. acquired a new stake in Abbott Laboratories in the fourth quarter valued at $25,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories during the 4th quarter worth $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in shares of Abbott Laboratories in the 4th quarter valued at about $26,000. Finally, Abound Financial LLC purchased a new stake in Abbott Laboratories during the fourth quarter worth about $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Performance

NYSE ABT opened at $111.46 on Friday. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $137.49. The firm has a market capitalization of $192.87 billion, a P/E ratio of 36.07, a P/E/G ratio of 2.21 and a beta of 0.59. The business’s 50-day simple moving average is $102.12 and its 200-day simple moving average is $100.13.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. During the same period in the previous year, the company posted $1.26 earnings per share. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts predict that Abbott Laboratories will post 5.52 EPS for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, August 17th. Investors of record on Wednesday, July 15th were issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 2.3%. The ex-dividend date was Wednesday, July 15th. Abbott Laboratories’s dividend payout ratio is currently 81.55%.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ABT. TD Cowen lifted their price target on shares of Abbott Laboratories from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday. UBS Group decreased their target price on Abbott Laboratories from $135.00 to $125.00 and set a “buy” rating on the stock in a research report on Tuesday, July 28th. Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. JPMorgan Chase & Co. lifted their price target on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. Finally, Citigroup upped their target price on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $119.50.

More Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketones. The device is cleared for diabetes patients age two and older and could strengthen Abbott’s Libre franchise, particularly as the company works toward integration with insulin pumps. What Does Abbott Laboratories FDA Clearance Mean for Its Diabetes Device Push?
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is intended to reduce stroke risk in patients with non-valvular atrial fibrillation and may reduce reliance on blood-thinning medication. Recent trial data reportedly met safety and effectiveness benchmarks, supporting Abbott’s structural-heart and electrophysiology businesses. Abbott Amulet 360 Receives CE Mark
• Positive Sentiment: TD Cowen analyst commentary indicated that Abbott’s stock could rise, providing an additional vote of confidence in the company’s outlook. TD Cowen Says Abbott Stock Could Rise
• Neutral Sentiment: The regulatory approvals are strategically important, but their financial benefits will depend on commercial adoption, reimbursement, competitive responses and the timing of integration with insulin-pump systems.
• Negative Sentiment: Abbott underperformed while the broader market gained. The pullback suggests that investors may be focusing on the stock’s relatively high valuation and the fact that the newly approved products are longer-term growth catalysts rather than immediate earnings drivers. Why Abbott Stock Declined as the Market Gained

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.